Summary

Results from IMPROVE-IT showed that adding ezetimibe to statin therapy with simvastatin significantly reduced the primary end point in moderate- to high-risk patients stabilized after acute coronary syndromes. A new analysis from IMPROVE-IT showed that the number of first and recurrent primary end point events was also reduced with combination therapy vs monotherapy over the median 6-year follow-up.